File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes

TitleThiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes
Authors
KeywordsChemicals And Cas Registry Numbers
Advanced glycation end-products
RAGE
Soluble receptor for advanced glycation end-products
Thiazolidinedione
Type 2 diabetes mellitus
Issue Date2007
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00125/index.htm
Citation
Diabetologia, 2007, v. 50 n. 9, p. 1819-1825 How to Cite?
AbstractAims/hypothesis: Interfering with the activation of receptor for AGE (RAGE) by using a soluble form of the AGE receptor (sRAGE) prevents or ameliorates the vascular complications of diabetes in experimental studies. Relatively little is known about factors that influence endogenous circulating sRAGE in humans. We investigated the impact of improving glycaemic control on serum total sRAGE and endogenous secretory RAGE (esRAGE), a splice variant of sRAGE, and compared the effect of rosiglitazone with that of sulfonylurea. Methods: A randomised, open-label, parallel group study was performed with 64 participants randomised to receive add-on therapy with either rosiglitazone or sulfonylurea. Serum total sRAGE and esRAGE and metabolic parameters were measured before and after 6 months of treatment. Results: At 6 months, both rosiglitazone and sulfonylurea resulted in a significant reduction in HbA1c, fasting glucose and AGE. However, significant increases in total sRAGE and esRAGE were only seen in the rosiglitazone group. As a result, serum esRAGE was higher in the rosiglitazone group than in the sulfonylurea group at 6 months (p < 0.01), whereas the differences in sRAGE between the two groups did not reach statistical significance. Stepwise linear regression analysis showed that treatment modality made a greater contribution than the changes in HbA 1c to the subsequent changes in esRAGE levels at 6 months. Conclusions/interpretation: Treating type 2 diabetic patients with thiazolidinedione can increase circulating levels of esRAGE and sRAGE. Whether modulation of circulating sRAGE has a beneficial effect on diabetic complications will have to be evaluated in long-term prospective studies. International Standard Randomised Controlled Trial Number ISRCTN05215453. © 2007 Springer-Verlag.
Persistent Identifierhttp://hdl.handle.net/10722/91515
ISSN
2015 Impact Factor: 6.206
2015 SCImago Journal Rankings: 3.528
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, KCBen_HK
dc.contributor.authorChow, WSen_HK
dc.contributor.authorTso, AWKen_HK
dc.contributor.authorXu, Aen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorHoo, RLCen_HK
dc.contributor.authorBetteridge, DJen_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2010-09-17T10:20:39Z-
dc.date.available2010-09-17T10:20:39Z-
dc.date.issued2007en_HK
dc.identifier.citationDiabetologia, 2007, v. 50 n. 9, p. 1819-1825en_HK
dc.identifier.issn0012-186Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/91515-
dc.description.abstractAims/hypothesis: Interfering with the activation of receptor for AGE (RAGE) by using a soluble form of the AGE receptor (sRAGE) prevents or ameliorates the vascular complications of diabetes in experimental studies. Relatively little is known about factors that influence endogenous circulating sRAGE in humans. We investigated the impact of improving glycaemic control on serum total sRAGE and endogenous secretory RAGE (esRAGE), a splice variant of sRAGE, and compared the effect of rosiglitazone with that of sulfonylurea. Methods: A randomised, open-label, parallel group study was performed with 64 participants randomised to receive add-on therapy with either rosiglitazone or sulfonylurea. Serum total sRAGE and esRAGE and metabolic parameters were measured before and after 6 months of treatment. Results: At 6 months, both rosiglitazone and sulfonylurea resulted in a significant reduction in HbA1c, fasting glucose and AGE. However, significant increases in total sRAGE and esRAGE were only seen in the rosiglitazone group. As a result, serum esRAGE was higher in the rosiglitazone group than in the sulfonylurea group at 6 months (p < 0.01), whereas the differences in sRAGE between the two groups did not reach statistical significance. Stepwise linear regression analysis showed that treatment modality made a greater contribution than the changes in HbA 1c to the subsequent changes in esRAGE levels at 6 months. Conclusions/interpretation: Treating type 2 diabetic patients with thiazolidinedione can increase circulating levels of esRAGE and sRAGE. Whether modulation of circulating sRAGE has a beneficial effect on diabetic complications will have to be evaluated in long-term prospective studies. International Standard Randomised Controlled Trial Number ISRCTN05215453. © 2007 Springer-Verlag.en_HK
dc.languageengen_HK
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00125/index.htmen_HK
dc.relation.ispartofDiabetologiaen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.subjectAdvanced glycation end-products-
dc.subjectRAGE-
dc.subjectSoluble receptor for advanced glycation end-products-
dc.subjectThiazolidinedione-
dc.subjectType 2 diabetes mellitus-
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshBlood Glucose - metabolismen_HK
dc.subject.meshBlood Pressureen_HK
dc.subject.meshBody Mass Indexen_HK
dc.subject.meshDiabetes Mellitus, Type 2 - blood - drug therapyen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGlyburide - therapeutic useen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypoglycemic Agents - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshReceptors, Immunologic - blood - drug effectsen_HK
dc.subject.meshThiazolidinediones - therapeutic useen_HK
dc.titleThiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetesen_HK
dc.typeArticleen_HK
dc.identifier.emailTan, KCB:kcbtan@hku.hken_HK
dc.identifier.emailTso, AWK:awk.tso@gmail.comen_HK
dc.identifier.emailXu, A:amxu@hkucc.hku.hken_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.emailHoo, RLC:rubyhoo@hkucc.hku.hken_HK
dc.identifier.emailLam, KSL:ksllam@hku.hken_HK
dc.identifier.authorityTan, KCB=rp00402en_HK
dc.identifier.authorityTso, AWK=rp00535en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.identifier.authorityHoo, RLC=rp01334en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00125-007-0759-0en_HK
dc.identifier.pmid17639302-
dc.identifier.scopuseid_2-s2.0-34547659641en_HK
dc.identifier.hkuros145512-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34547659641&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume50en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1819en_HK
dc.identifier.epage1825en_HK
dc.identifier.isiWOS:000248771800006-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridTan, KCB=8082703100en_HK
dc.identifier.scopusauthoridChow, WS=7402281153en_HK
dc.identifier.scopusauthoridTso, AWK=6701371436en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridHoo, RLC=6602369766en_HK
dc.identifier.scopusauthoridBetteridge, DJ=34973752700en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats